Edition:
United Kingdom

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

49.33USD
6:32pm BST
Change (% chg)

$-0.24 (-0.48%)
Prev Close
$49.57
Open
$49.44
Day's High
$49.83
Day's Low
$48.98
Volume
127,341
Avg. Vol
394,962
52-wk High
$71.31
52-wk Low
$45.31

Latest Key Developments (Source: Significant Developments)

Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin
Monday, 26 Mar 2018 

March 26 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.SEATTLE GENETICS INC - COS ARE ALSO EVALUATING ENFORTUMAB VEDOTIN IN OTHER SOLID TUMORS, INCLUDING OVARIAN AND NON-SMALL CELL LUNG CARCINOMA.  Full Article

Seattle Genetics Announces FDA Approval Of Adcetris
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) IN COMBINATION WITH CHEMOTHERAPY FOR ADULTS WITH PREVIOUSLY UNTREATED STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA.SEATTLE GENETICS INC - ‍PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE MAY 1, 2018​.SEATTLE GENETICS INC - ‍FDA ALSO GRANTED PRIORITY REVIEW FOR SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ADCETRIS​.  Full Article

Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Seattle Genetics Inc ::FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) IN FRONTLINE ADVANCED HODGKIN LYMPHOMA.SEATTLE GENETICS INC - FDA GRANTED PRIORITY REVIEW FOR APPLICATION, AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS MAY 1, 2018.  Full Article

TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍CHMP POSITIVE OPINION FOR ADCETRIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​.‍EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINION FOR EXTENSION OF MARKETING AUTHORIZATION OF ADCETRIS​.‍CHMP RECOMMENDED ADCETRIS​ ITS APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍SEATTLE GENETICS AND TAKEDA ARE JOINTLY DEVELOPING ADCETRIS​.  Full Article

SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF).SEATTLE GENETICS INC - ‍FDA ALSO GRANTED PRIORITY REVIEW FOR SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ADCETRIS​.SEATTLE GENETICS INC - ‍PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE FOR ADCETRIS WAS DECEMBER 16, 2017​.  Full Article

Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Seattle Genetics Inc :Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer.Primary objective of trial is to assess safety and tolerability of Enfortumab Vedotin in combination with CPI therapy​.  Full Article

Seattle Genetics submits supplemental license application for Adcetris
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Seattle Genetics Inc :Seattle genetics submits supplemental biologics license application to FDA for Adcetris (brentuximab vedotin) in frontline advanced hodgkin lymphoma.  Full Article

Seattle Genetics reports Q3 earnings $0.34/shr
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Seattle Genetics Inc :Seattle Genetics reports third quarter 2017 financial results.Q3 earnings per share $0.34.Q3 revenue $135.3 million versus I/B/E/S view $112.8 million.Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Seattle Genetics Inc sees FY 2017 ‍revenues from collaboration and license agreements $90 million to $100 million​.Seattle Genetics Inc sees ‍fy 2017 royalty revenues $60 million to $65 million​.  Full Article

Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Astellas Pharma Inc <4503.T>::Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.Seattle Genetics Inc - ‍companies also plan to initiate a combination trial of enfortumab vedotin with CPI therapy in late 2017​.  Full Article

Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Genmab A/S :Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer.Genmab - ‍companies plan to start enrolling patients by first half of 2018​.Genmab - ‍co, Seattle Genetics to start phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer​.  Full Article

Biotech group Genmab aims to own bigger share of new drug pipeline

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.